This article was originally published in The Tan Sheet
The House Energy and Commerce Subcommittee on Oversight and Investigations announces Aug. 24 it is investigating FDA's plan to outsource jobs. Energy and Commerce Chairman John Dingell, D-Mich., and Subcommittee Chair Bart Stupak, D-Mich., say in a release they were "incredulous" when they learned of FDA's plan to outsource 332 positions. The news comes one week after Dingell and Stupak commended the Office of Regulatory Affairs' plan to shut down seven labs (1"The Tan Sheet" Aug. 27, 2007, p. 6). The congressmen are asking for a list of the positions as well as descriptions of job responsibilities, records reflecting the plans, budget analyses and more by Sept. 7...
You may also be interested in...
FDA's head of regulatory affairs' Aug. 17 message to staff about cancelling plans to close seven field labs did not mark the end of the agency's ORA reorganization work, staff members say
As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.
More option deals, greater use of alternative remedy clauses and aggressive diligence of assets. Geoffrey Spolyar, special counsel at Cooley, spotlights some of the changes he is seeing in pharma and biotech partnership agreements and explains why these trends matter in 2021.